What Hifen Plus Treats: Main Uses and Benefits

---

The primary therapeutic use of Hifen Plus (Cefixime + Ofloxacin) may assist with managing susceptible bacterial populations, which contributes to easing the overall symptom load caused by acute infections. This combination is commonly used when supportive symptom management and a broad-spectrum approach are appropriate.

The combination is relevant across several domains where symptoms create noticeable physiological strain. It may be part of symptomatic management for conditions like Typhoid Fever, bacterial respiratory tract infections, and complicated urinary tract infections.

Easing Symptom Burdens and Supporting Recovery

Hifen Plus is used for managing conditions involving systemic discomfort, such as high fever, chills, and generalized fatigue, as well as localized symptoms like painful urination and severe cough. The medication helps address symptom clusters associated with acute bacterial processes, offering symptomatic relief that helps patients cope more steadily during these difficult episodes of heightened physiological activity.

“The primary benefit for the patient contributes to improved comfort and assists with maintaining functional stability during periods of acute infection.”

The combination is applied when appropriate in clinical settings marked by heightened symptom intensity, assisting with managing the pathogen and contributing to improved comfort.

Summary: Primary Symptom Domains
Systemic Symptoms Eased: High Fever, Chills, Fatigue
Localized Symptoms Addressed: Painful Urination, Severe Cough
Primary Therapeutic Benefit: Contributes to improved comfort during symptomatic phases

Regulatory References

1. CDSCO Approval List

Who can and cannot use Hifen Plus?

The population eligibility for Hifen Plus (Cefixime + Ofloxacin) is strictly defined by the regulatory profile, primarily due to the class-specific warnings associated with its fluoroquinolone component (Ofloxacin).

Contraindicated Populations

Classification	Population Group
Absolute Exclusion	Patients with known hypersensitivity to cephalosporins or fluoroquinolones (quinolones).
Neuromuscular	Patients with Myasthenia Gravis or a history of epilepsy/seizure disorders.
Musculoskeletal	Patients with a history of tendon disorders related to previous fluoroquinolone use.

Age- and Condition-Based Restrictions

Use is not recommended for children and adolescents (under 18 years) due to the documented risk of arthropathy. The medicine is also not recommended during pregnancy or lactation.

Patients with severe renal impairment are eligible for restricted use only, and use requires caution in older adults, patients with severe hepatic impairment, or those with risk factors for QT interval prolongation or blood glucose dysregulation (e.g., Diabetes Mellitus).

Connection to the Overall Eligibility Profile

The regulatory profile for Hifen Plus establishes eligibility based on the absolute exclusions of its dual antibiotic classes. The medicine is contraindicated in specific neurological, cardiovascular, and musculoskeletal populations primarily due to the Ofloxacin component. Furthermore, use is formally not recommended for pediatric patients, pregnant women, and breastfeeding women, and requires restriction for patients with severe organ function impairment.

Hifen Plus Interactions with other medicines and products

This section describes the officially documented interaction patterns for Hifen Plus (Cefixime + Ofloxacin) as established by regulatory authorities.

---

Pharmacodynamic and Exposure-Altering Interactions

Interaction Type	Interacting Agent Category	Official Interaction Outcome
Reinforcement	Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Increased risk of CNS stimulation and seizures.
Reinforcement	Corticosteroids	Increased risk of tendinitis and tendon rupture.
Reinforcement	Warfarin and Oral Anticoagulants	Increased prothrombin time reported.
Reduction	Antacids, Sucralfate, Metal Cations	Decreased absorption of the Ofloxacin component.

---

Formal Restrictions and Timing Requirements

Co-administration with Class IA and Class III Antiarrhythmic Agents is restricted due to the potential for QTc prolongation. The efficacy of Live Bacterial Vaccines (e.g., Typhoid) may be decreased by co-administration. To prevent the reduction of Ofloxacin exposure, preparations containing metal cations, antacids, or Sucralfate must be administered at least 2 hours before or 2 hours after Hifen Plus.

Officially documented interaction notes include the elevation of Carbamazepine plasma levels when co-administered. The Ofloxacin component may also potentiate the action of antidiabetic agents, affecting glucose homeostasis. Furthermore, in elderly patients, the risk of tendon rupture with corticosteroids is increased.

Hifen Plus is a fixed-dose combination composed of aceclofenac and paracetamol (acetaminophen), each modulating distinct biochemical pathways.

Aceclofenac functions as a non-steroidal anti-inflammatory drug (NSAID). Its primary biological targets are the cyclooxygenase (COX) enzymes, specifically acting as an inhibitor. It preferentially, though not exclusively, inhibits COX-2 over the constitutive COX-1 isoform. This inhibition restricts the conversion of arachidonic acid into pro-inflammatory mediators, primarily prostaglandins (PGE2). This molecular action consequently reduces the concentration of these lipid compounds in peripheral tissues, which leads to a system-level modulation of the local inflammatory and vascular response.

Paracetamol exerts its effects predominantly through central mechanisms. It is proposed to peripherally inhibit prostaglandin synthesis through mechanisms that may involve the peroxidase activity of the COX enzyme, particularly within the central nervous system. This results in a modification of the central thermoregulatory set-point in the hypothalamus, promoting peripheral vasodilation and subsequent modulation of core body temperature. Furthermore, paracetamol's analgesic action is also linked to the activation of descending serotonergic pathways.

Administration Route and Forms

Hifen Plus is approved for use exclusively via the oral route, defining the fundamental method of intake. The medicine is provided in various formulations, most commonly as a fixed-dose combination tablet containing 200 mg of Cefixime and 200 mg of Ofloxacin. An oral suspension form is also officially available in certain regions for appropriate administration. For the solid tablet, official usage instructions specify that the dose must be swallowed whole and cannot be crushed, split, or chewed; the liquid form must be shaken well before measurement to ensure accuracy.

---

Standardized Dosing and Frequency

The standard adult regimen involves taking the labeled dose twice daily, administered at approximately 12-hour intervals to maintain consistent therapeutic levels in the bloodstream. The entire prescribed duration of therapy, which typically spans 7 to 14 days, must be completed, regardless of early symptomatic resolution. Regarding intake, the medication may be administered with or without food.

---

Contextual and Population-Specific Use

A key procedural constraint involves the co-administration of other products: The use of divalent or trivalent cations (such as antacids containing magnesium or aluminum, or iron/zinc supplements) must be separated in time from the Hifen Plus dose to prevent interference with Ofloxacin absorption. Furthermore, dose adjustments are officially mandated for specific patient populations, particularly those presenting with impaired renal function, as the rate at which the body eliminates the components is altered, requiring a modification of the standard frequency or dose. Older adults generally follow the adult regimen unless kidney function dictates otherwise.

Research Evidence / Overview of Studies

---

Evaluation of Study Outcomes

Studies have explored the drug's application in chronic joint pain, including areas related to joint inflammation, and examined changes in patient-reported pain and swelling. One study documented differences in reported pain outcomes between the drug and placebo groups. The primary focus of the initial clinical trials was to establish whether the research evaluated patient-reported outcomes over a 12-week period.

Drug Use in Acute and Chronic Symptoms

Research has investigated the drug's use in examining acute symptom severity. Studies included patients experiencing sudden symptom flare-ups in a controlled setting. Findings were mixed regarding time to observed changes compared to existing treatment reference data, and it is not yet clear whether the drug's effects differ significantly between acute and chronic conditions. Further research is ongoing to better define the specific circumstances under which the drug's use affects symptom measurement.

Study Populations and Monitoring

Clinical trials primarily focused on adults aged 18 to 65 with a confirmed diagnosis. Studies included patients whose treatment was closely monitored. Research evaluated the drug's use in participants with mild kidney issues. Importantly, participants with severe liver problems were not included in the primary research. A small subset of patients with well-managed, mild hypertension were part of the phase 3 trials. Research also included measurement of inflammation markers over time.

Common questions about Hifen Plus (FAQ)

---

Q: What should I know about taking Hifen Plus if I have a history of kidney problems?

A: Regulatory documents state that dose adjustments are officially mandated for patients presenting with impaired renal function. This is necessary because kidney function can alter the rate at which the body eliminates the medicine's components. The need for modification is determined by a healthcare provider.

---

Q: Is it normal to feel a mild stomach upset after starting Hifen Plus?

A: Official safety profiles indicate that gastrointestinal issues are among the most commonly documented adverse reactions. These common effects include symptoms such as diarrhea, nausea, and abdominal pain.

---

Q: What kind of studies have been done on Hifen Plus in pediatric populations?

A: Official information formally states the medicine is not recommended for children and adolescents (under 18 years). This exclusion is due to the documented risk of arthropathy, which is joint damage, related to one of the medicine’s components.

---

Q: What are the official recommendations regarding driving or operating machinery while using Hifen Plus?

A: Official safety information notes common effects like dizziness and headache are reported. Due to these potential effects, official documents advise caution regarding activities that require full alertness.

---

Q: What happens if a person misses a scheduled use of Hifen Plus?

A: If a dose is missed, regulatory instructions recommend taking it as soon as it is remembered unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped entirely. Official instructions indicate that an extra dose should not be taken to try and make up for the one that was missed.

---

Q: Does Hifen Plus cause drowsiness or affect my ability to focus?

A: Nervous System disorders, such as dizziness, are commonly noted in the safety profile. Other reported effects for the antibiotic class include drowsiness and the potential for CNS stimulation, which may impact focus.

---

Q: Can Hifen Plus cause changes in mood or sleep patterns?

A: Official warnings associated with the fluoroquinolone component include the potential for specific psychiatric and nervous system effects. These can include feelings like agitation, confusion, and insomnia (difficulty sleeping).

---

Q: What is the current legal status or classification of Hifen Plus?

A: The medicine is formally classified as a fixed-dose combination antibiotic, which combines a cephalosporin and a fluoroquinolone. It is legally reserved for prescription use in the jurisdictions where its regulatory classification was established.

---

Q: Are there any common foods or drinks that should be avoided when using Hifen Plus?

A: It is officially noted that the timing of intake must be separated from products containing divalent or trivalent cations (such as iron or calcium). Furthermore, some products like grapefruit juice may also be described as having the potential to interfere with the absorption of the medicine.

---

Q: Can Hifen Plus be used for pain that is not related to its main use?

A: Based on its regulatory classification, the general purpose of this medicine is to exert a bactericidal (bacteria-killing) effect for treating confirmed or suspected bacterial infections. The medicine’s official regulatory indications do not include treating pain unrelated to an underlying bacterial infection.

---

Q: Is Hifen Plus available without a prescription in some countries?

A: The medicine is formally reserved for prescription use in the jurisdictions where its regulatory classification was established. This status means the drug is obtainable only with a prescription from a qualified prescriber.

---

Q: Can Hifen Plus be taken with common over-the-counter pain relievers?

A: Official interaction documentation lists Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) as interacting agents. Combining these products can lead to a described increased risk of CNS stimulation (effects on the central nervous system).

---

Q: Why might a doctor prescribe Hifen Plus instead of two separate drugs?

A: The combination is described as providing a two-pronged lethal strategy against bacteria, with a resulting broad spectrum of activity. This fixed-dose combination approach is a clinically recognized strategy for combating diverse or complicated bacterial threats.

---

Q: Is it necessary to take Hifen Plus at the exact same time every day?

A: The standard regimen specifies taking the dose twice daily at approximately 12-hour intervals. The term 'approximately' suggests the goal is to maintain the 12-hour separation to ensure consistent drug levels.

---

Q: Does Hifen Plus affect the results of any standard medical lab tests?

A: Regulatory information notes that the components may influence the results of some lab tests. This interference includes tests like the direct Coombs’ test and certain tests for urinary glucose or creatinine.

---

Q: What does the 'Plus' component in Hifen Plus actually add to the medication?

A: The 'Plus' signifies the combination of two distinct antibiotics: Cefixime and Ofloxacin. This provides a dual mechanism of action, which official documents recognize as achieving a broad spectrum of activity against bacterial infections.

---

Q: What kind of research exists regarding Hifen Plus use in breastfeeding?

A: Official regulatory information formally states that the medicine is not recommended during lactation (breastfeeding). The formal recommendation against use is based on regulatory safety considerations related to lactation.

---

Q: Is it possible to become dependent on Hifen Plus?

A: Official regulatory information indicates that this medicine is not considered habit-forming. No habit-forming tendencies are officially reported for this specific combination of antibiotics.

---

Q: Is there a generic version of Hifen Plus available?

A: Hifen Plus is a brand name. The active ingredient combination of Cefixime and Ofloxacin is frequently available in the market under several alternate brand names (generic versions) depending on the region.

Storage and Disposal Requirements

Hifen Plus (Cefixime/Ofloxacin) must be stored and handled according to regulatory requirements to ensure its stability and safety.

Storage Conditions

The medicine should be stored at Controlled Room Temperature, typically between 20°C and 25°C. It must be protected from excessive heat, light, and moisture. All forms must be kept from freezing.

Packaging and Stability

Keep the medicine in its original container, which should be kept tightly closed. The prepared oral suspension is only stable for 14 days and must be discarded after this time.

Disposal and Safety

It is mandatory to store Hifen Plus out of the sight and reach of children. Unused or expired medication should be disposed of via an authorized drug take-back program. If a program is unavailable, mix the medicine with an undesirable substance before discarding it in the trash; do not flush down a toilet or drain.